17:35 , Nov 29, 2017 |  BioCentury  |  Emerging Company Profile

Gluten-free gut

PvP Biologics Inc. is developing an oral enzyme therapy for celiac disease to break down gluten in the stomach with more specificity than a competing enzyme cocktail. The company’s KumaMax, a synthetic peptidase, should prevent...
22:54 , Nov 17, 2017 |  BioCentury  |  Finance

Stepwise progress

After six years and four Phase I trials ImmusanT Inc. has finally nailed down the optimal dose regimen for celiac disease vaccine Nexvax2 and is ready to take the leap into Phase IIb testing with...
05:08 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Venture roundup: ImmusanT, Locus

On Nov. 14, autoimmune company ImmusanT Inc. (Cambridge, Mass.) and antimicrobial play Locus Biosciences Inc. (Research Triangle Park, N.C.) announced venture financings totaling nearly $60 million. ImmusanT raised $40 million in a series C round led...
00:11 , Nov 15, 2017 |  BC Extra  |  Financial News

Venture Roundup: ImmusanT, Locus

On Tuesday, autoimmune company ImmusanT Inc. (Cambridge, Mass.) and antimicrobial play Locus Biosciences Inc. (Research Triangle Park, N.C.) announced venture financings totaling nearly $60 million. ImmusanT raised $40 million in a series C round led by...
00:30 , Oct 12, 2017 |  BC Innovations  |  Product R&D

Artificial mini proteins

Virvio Inc. has spun out of a group from the University of Washington to develop artificial mini proteins as novel influenza therapeutics. The mini proteins, typically ranging between 30 and 50 amino acids in length,...
16:25 , Mar 17, 2017 |  BC Week In Review  |  Clinical News

Nexvax2: Ph Ib data

A double-blind, placebo-controlled, Australian and New Zealand Phase Ib trial in 38 celiac disease patients on a gluten-free diet showed that twice-weekly intradermal Nexvax2 for up to 60 days was well tolerated and led to...
18:43 , Jan 11, 2017 |  BC Week In Review  |  Company News

PvP, Takeda deal

The companies partnered to develop PvP's preclinical celiac disease candidate, KumaMax. PvP will conduct R&D through Phase I trials, and Takeda will provide $35 million. The pharma will also have an exclusive option to acquire...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Company News

Intrexon, Genten deal

Intrexon granted newco Genten exclusive access to Intrexon’s ActoBiotics technology to deliver gluten peptide therapies to promote immune tolerance in patients with celiac disease. The ActoBiotics technology delivers therapeutic proteins and peptides to the GI...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Company News

Alvine, Immunogenics deal

Immunogenics’ ImmunogenX subsidiary acquired Alvine’s non-cash assets, including latiglutenase and three celiac disease patient-reported outcome tools. Latiglutenase is a combination of a cysteine protease (EP-B2) and a proline-specific prolyl endopeptidase (PEP) engineered...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Clinical News

Larazotide: Phase IIb data

The double-blind, North American Phase IIb CLIN1001-012 trial in 342 celiac disease patients who have persistent symptoms despite being on a gluten-free diet showed that thrice-daily oral larazotide met the primary endpoint of improving the...